Aspirin (acetylsalicylic acid) inhibits platelet prostaglandin synthesis and the ADP-and collagen-induced platelet release reaction. The mechanism of the inhibitory effect is unknown but may involve protein acetylation, since aspirin acetylates a variety of substrates, including platelet protein. We have examined the relationship between protein acetylation and aspirin's physiologic effect on platelets. Suspensions of washed human platelets were incubated at 37 degrees C with (3H)aspirin, and incorporation of radioactivity into protein was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Exposure to (acetyl-3H)aspirin but not (aromatic ring-3H)aspirin resulted in radioactive labeling of three platelet proteins, suggesting that the drug acetylates these three proteins. The acetylation of two of the proteins (located in the supernatant fraction) was not saturable, implying that these reactions may not be physiologically significant. Acetylation of the third protein, approximate mol wt 85,000 (located in the particulate fraction), saturated at an aspirin concentration of 30 muM and was complete within 20 min. Platelets prepared from aspirin-treated donors did not incorporate any (acetyl-3H)aspirin radioactivity into the particulate protein for 2 days after drug treatment and did not show full pretreatment uptake of radioactivity for 12 days thereafter. The course of increasing incorporation of (acetyl-3H)aspirin radioactivity parralleled that of platelet turnover. Therefore, in addition to its saturability, acetylation of the particulate fraction protein by aspirin was permanent. [acetyl-'H]aspirin radioactivity paralleled that of platelet turnover. Therefore, in addition to its saturability, acetylation of the particulate fraction protein by aspirin was permanent.
In two respects, the inhibition of platelet function by aspirin correlates well with the aspirin-mediated acetylation of the particulate fraction protein. Both per-
INTRODUCTION
The household analgesic, aspirin (acetylsalicylic acid), has an alternate role as an inhibitor of platelet function. The effect of aspirin on platelets has been studied at many levels. Clinically, aspirin has modest effects on hemostasis in normal individuals (1) but may induce markedly prolonged bleeding times in hemophiliacs (2) . When platelet function is studied in vitro, aspirin has been shown to inhibit the platelet release reaction. The inhibitory effect has several features: (a) Maximal inhibition is produced by relatively low concentrations (<50 uM) of aspirin either in vivo or in vitro. (b) Inhibition is permanent in that the release reaction of an aspirin-treated platelet is affected for the life-span of the platelet. (c) Inhibition is selective in the sense that aspirin appears to be more effective in inhibiting release induced by some agents (ADP and collagen) (3, 4) than by another (thrombin) (5) .
Aspirin also inhibits the formation of prostaglandin G2, a cyclic endoperoxide intermediate of prostaglandin biosynthesis in human platelets (6, 7) . Recent studies indicate that prostaglandin G2 production is stimulated by thrombin and that isolated prostaglandin G2 will cause platelet aggregation and the release reaction (8, 9) .
Despite these extensive investigations, the mechanism of action for aspirin's effect on platelets remains unclear. The results of previous studies have shown that aspirin can acetylate platelet protein (10 Assay of aspirin. Neutral hydroxylamine reacts with the acetyl group of aspirin to form acetyl hydroxamate which can be assayed with ferric chloride reagent by measuring absorbance at 540 nm (12) . Aqueous solutions of aspirin (0-10 Amol) were mixed with 0.5 ml of neutral hydroxylamine (2 M), and water was added to give a total volume of 1.5 ml. The solution was incubated for 10 min at room temperature. Ferric chloride reagent (1.5 ml) was added, and absorbance at 540 nm was determined. The concentration of aspirin in test solutions was determined by comparison to a standard curve: E1o = 30,700. a Nonradioactive salicylic acid was added to [G-3H] salicylic acid to give the specific activity of 200 GCi/,Amol.
Effect of Aspirin on Human Platelets
For analysis by TLC, aspirin and salicylic acid (0.1 umol), mixed with trace amounts of radioactive aspirin (0.007-0.04 pmol), were applied to silica gel plates and subjected to TLC in two solvent systems: (a) n-butanol: pyridine: dioxane: H20 (70: 20: 5: 5, by volume) ; (b) Benzene: diethyl ether: glacial acetic: methanol: (120: 60: 18:1, by volume). Salicylate spots were visualized under ultraviolet light. Radioactivity was localized by scraping 1-cm strips of gel from the TLC sheets into scintillation fluid (3a70). The radioactivity of the suspended silica gel was measured in a liquid scintillation counter.
Salicylate preparations were analyzed by gas-liquid chromatography (GLC) using the method of Thomas, Solomonraj, and Coldwell (13) . Aspirin or salicylic acid (2 ,gmol) was incubated with 0.05 ml N,O-bis-trifluoroacetimide to convert the salicylate to the trimethylsilyl derivative. By comparison with standards, the salicylic acid and aspirin contents of a synthesized tritiated aspirin preparation were determined. The content of tritium in the aspirin and salicylic acid peaks eluted from the GLC column was measured by collecting effluent gas from the column into cold ethanol (-700C) and counting aliquots of the ethanol in a liquid scintillation counter.
PLATELETS
Human blood was collected into one-sixth volume of acid-citrate-dextrose (0.085 M sodium chloride, 0.065 M citric acid, 0.111 M D-glucose). Washed platelets were prepared after the method of Ardlie and Han (11), omitting bovine serum albumin from wash and resuspension buffers. For experiments on platelets suspended in acetate-containing media, sodium acetate, 0.10 M, with sodium chloride, 0.04 M, was substituted for sodium chloride, 0.14 M, the concentration generally used in Tyrode's solution. For gel electrophoresis of sonicated platelet fractions, suspensions of platelet material were made in protein-free Tyrode's solution, pH 7.3.
A "microhematocrit" method was used to estimate the number of platelets in suspensions as previously described (14) .
INCORPORATION OF RADIOACTIVE ASPIRIN INTO PLATELETS
Incorporation into whole platelets and trichloroacetic acid (TCA ) -treated whole platelets. The incorporation of radioactive aspirin into whole platelets and TCA precipitates of whole platelets was assessed by the following method. Platelet suspensions, 2.5 X 10k-10.0 X 108 platelets/ml, were incubated at 370C with either [acetyl-1-"4C] aspirin or [acetyl-8H]aspirin at final concentrations of 50-500 itM.
At varying times, the platelet suspension was layered above 1 ml of 0.25 M sucrose in a siliconized Hopkin's vaccine tube (Pyrex tube 8225, Corning Glass Works, Corning N. Y.) and centrifuged at 2,000 g for 15 min. Centrifugation of platelets through the sucrose solution served to remove nonplatelet-bound aspirin from the platelet pellet. The sucrose and media overlying the platelet pellet was removed by aspiration. The platelet pellet was dispersed in buffer, and an aliquot was assayed for radioactivity. A volume of cold 10% TCA equal to that of the remaining platelet suspension was added, and the suspension was centrifuged at 12,000 g for 15 min. The TCA precipitate was solubilized in NCS. Aliquots of the whole platelet suspension, TCA supernatant, and NCS-solubilized TCA precipitate were added to 3a70 and counted in a liquid scintillation counter.
Gel electrophoretic analysis of radioactively labeled platelet protein. Washed platelet suspensions containing 1 X 109 platelets/ml were incubated with aspirin for varying times at 370C. In experiments involving platelet fractionation, the platelet suspension was cooled to 40C after 20 min incubation, and diisopropyl fluorophosphate (10 mM) was added immediately before platelet disruption to inhibit proteolysis. Cells were broken by sonication (30 s 70% intensity) using a Biosonic sonicator with microprobe attachment (Biosonic II, Bronwill Scientific, Rochester, N. Y.) and the suspension was centrifuged at 200,000 g for 45 min. The supernatant fraction was decanted and saved. The pellet of particulate material was dispersed in one-half the original volume of buffer.
Radioactively labeled whole platelets and sonicated platelet fractions were subjected to sodium dodecyl sulfate (SDS) 8 polyacrylamide gel electrophoresis after the method of Weber and Osborn (15) . An aliquot of labeled whole platelet suspension (0.11 ml) or sonicated platelet fraction (0.10 ml) was mixed with 0.025 ml of 20% SDS in 0.1 M sodium phosphate buffer, (pH 7.4)-0.5 M 2-mercaptoethanol, placed in a boiling water bath for 10 min, and applied to a gel of 4.9%o polyacrylamide. To study labeling of whole platelets at zero time, 0.025 ml of the 20% SDS-2-mercaptoethanol solution was added initially to 0.1 ml of whole platelet suspension, and the sample was boiled for 5 min. Then 0.01 ml of aspirin solution was added, and boiling was continued for an additional 5 min. Electrophoresis was carried out in cylindrical gels (0.5 X 10 cm) at ambient temperature using 8 mA/gel for 31 h.
Gels were stained for 12 h in 0.03%o Coomassie Blue, 50%o methanol, 12%o TCA, and destained in 10%o methanol, 7%
glacial acetic acid for 24 h. Destained gels were frozen on solid C02 slabs and sectioned at 2.14-mm intervals using a razor blade-type gel slicer (Bio-Rad Laboratories). Gel slices were placed in scintillation vials and extracted for 24 h at 37°C after the method of Ames (16) . Radioactivity was measured in a liquid scintillation counter at ambient temperature. Each vial containing radioactivity above background was counted for the time required to reach a counting error of 7% at a 95% confidence level.
The extraction of tritium radioactivity from the gel slices appeared to be complete. Removing the swollen gel slice from the vial after the extraction step did not lead to any reduction in radioactivity in the remaining scintillation fluid, indicating that the gel slice itself did not contain measurable tritium radioactivity.
Characterization of acetylated particulate fraction protein. In an effort to characterize the protein in a preliminary fashion, we treated the acetylated radioactively labeled protein in a particulate fraction prepared from 2 X 108 platelets as follows: (a) Incubation with pronase or trypsin, 0.2 mg/ml, at 37°C for 6 h. (b) Incubation with RNAse, 0.2 mg/ml, at 37°C for 6 h. Controls for each treatment were incubated at the same temperature for the same time period, but buffer was added instead of the active agent. The control and treated particulate fractions were then subjected to SDS gel electrophoresis, and the position of the radioactively labeled protein in the gel was determined as previously described.
The molecular weights of radioactively labeled platelet proteins were estimated by comparing the migration of labeled proteins in a SDS gel to that of proteins of known molecular weight. Seven known proteins were used: human platelet myosin (mol wt 230,000), Escherichia coli B-galactosidase (130,000), human fibrinogen alpha chain (73,000), 8Abbreviation used in this paper: SDS, sodium dodecyl sulfate. Fig. 3 . The incorporation of radioactivity into the 85,000 mol wt protein reaches maximal levels at aspirin concentrations between 30 and 100 AM.
The saturation characteristics of the reaction suggest that it is physiologically significant since the saturating concentration of 30 AM with a 20-min time-course correlates well with in vitro observations of aspirin inhibition of platelet function (4). In contrast, the uptake of radioactivity into the two soluble platelet proteins of mol wt 225,000 and 55,000 increases progressively with increasing aspirin concentrations between 0 and 300 LM under the conditions used. The fact that the incorporation of [acetyl-3H]aspirin radioactivity into these two proteins is not saturable indicates that these acetylation reactions do not correlate with the physiologic effect of aspirin on platelets. The nonsaturable acetylation of the two platelet proteins resembles the effect of aspirin in acetylating a variety of other proteins such as albumin, immunoglobulins, and fibrinogen (18) . (3, 10, 30, 100, and 300 jiM) and sonicated. Supernatant and particulate fractions were analyzed as in Fig. 2 (2 X 108 platelets/gel), and the number of counts per minute in each labeled protein peak was estimated. Incorporation of radioactivity into the 55,000 mol wt protein peak was linear up to 300 /AM aspirin (1,550 cpm). Label dilution experiments of the same type as shown in Fig. 4 Three normal male subjects ingested a total of 3 g of aspirin over 16 hr. Salicylate levels of 10-20 mg/100 ml (500-1,000 gM) were found in the serum of the subjects after the last done (20) . Platelets were collected from each subject at five times (0, 1, 3, 6, and 13 days) after the last aspirin dose. The washed platelets were incubated with 100 iuM [acetyl-8H]aspirin, and the particulate fraction of sonicated platelets was prepared and analyzed for radioactivity.
In Fig. 5 , the radioactivity content of the labeled 85,000 mol wt protein is plotted against time after aspirin ingestion. No labeling of this protein was seen on day 0 or day 1, indicating that acetylation of the protein was completely inhibited. Increasing amounts of label were incorporated on days 3 and 6, and essentially full uptake was seen on day 13. The course of increasing acetylation of the particulate fraction protein parallels platelet turnover, substantiating the idea that acetylation of this protein by aspirin is a permanent effect.
DISCUSSION
The observation that aspirin acetylates proteins and other biologic substrates is not new. Aspirin (500 uM) acetylates human serum albumin at a single site leading to the formation of e-N-acetyl lysine residues (21) . The drug (2.0-20 mM aspirin) acetylates hemoglobin at several sites within the molecule perhaps through the formation of e-N-acetyl lysines (22) . Less well characterized is the acetylation by aspirin (500 uM) of RNA, hormones, and various other serum proteins (18) . However, the search for a connection between protein acetylation and aspirin's physiologic effect has been a frustrating one. The point is well illustrated by the case of aspirin's effect on platelets. The drug has a definite and well-defined role as an inhibitor of platelet function. Furthermore, aspirin acetylates platelet protein (10) . However, no convincing evidence has been presented previously that the mechanism of aspirin's effect on platelets involves protein acetylation (10, 17) .
Such evidence could not be obtained in earlier studies due to the methodology used. Using [acety-l-C]-aspirin and [acetyl-8H]aspirin of low specific activity, prior investigators studied the incorporation of radioactivity into whole platelets and TCA precipitates of whole platelets. These methods were not suitable for distinguishing saturable from nonsaturable acetylation reactions for two reasons. First, the absolute amount of radioactivity transferred to platelet proteins at low aspirin concentrations was relatively small and difficult to measure due to the low specific activity of the radioactive aspirin. striking and implies that aspirin inhibits platelet function by acetylation of the particulate protein.
The physical characteristics and function of the acetylated particulate protein have not been thoroughly explored. The acetylation reaction may involve the formation of N-acetyl bonds in the protein, but the actual product of the reaction is unknown. One could speculate that the acetylated protein is related to an enzyme of prostaglandin biosynthesis. Samuelsson and co-workers have described the pathways of prostaglandin biosynthesis in several tissues (23) . In particular, they have identified a cyclic endoperoxide intermediate (prostaglandin G2) of prostaglandin synthesis in human platelets (9) . The endoperoxide has been implicated as a mediator of the platelet release reaction induced by ADP and collagen (8, 9) . In addition, the enzyme (cyclo-oxygenase) responsible for the synthesis of prostaglandin Gs is located in the particulate fraction of human platelets (24) and is inhibited "permanently" by low concentrations (approximately 50 *rM) of aspirin (6, 7, 25) . Therefore the position within the platelet and the susceptibility to aspirin inhibition of the acetylated particulate protein described in this study correlate with the same aspects of the prostaglandin G2 synthetic enzyme of human platelets studied by other investigators.
The acetylation of the particulate fraction protein by aspirin occurs at drug concentrations 10-to 100-fold lower than so-called "nonspecific" acetylations of albumin and hemoglobin (18, 21, 22) . The striking specificity of the former reaction suggests that aspirin is a site-specific agent in acetylating the platelet protein.
If the particulate fraction protein proves to be cyclooxygenase, aspirin may inhibit the enzyme by acetylating a single site (perhaps an active site) in the molecule. Therefore, aspirin may exert its antiplatelet effect by acetylating a residue within an active site of the prostaglandin G2 biosynthetic enzyme, cyclo-oxygenase. Finally, [acetyl-8H] aspirin may prove to be a useful probe in detecting sites of prostaglandin synthesis and have application in studies of organ physiology.
